Translational research

Bridging drug discovery and clinical development

Translational research

Bridging drug discovery and clinical development

The translational research stage of R&D takes promising drug candidates from drug discovery to early clinical development.

We work with our partners to assess the safety and tolerability of new drug candidates, develop drug formulations, establish dosing requirements, and study the risk of potential interactions with other drugs, before moving to Phase I studies in healthy human volunteers. A promising compound that successfully passes these early drug development steps can then advance to Phase II proof-of-concept studies in a limited number of patients to assess whether the drug has the desired effect on the target disease.

Our translational research projects

Loading…
Translational research

Chagas biomarkers

Proving treatment efficacy remains a challenge. The lack of a reliable test to monitor treatment efficacy is a major hurdle for developing new drugs for Chagas disease. We are supporting research and raising awareness of the need for ‘biomarkers’ that can be measured with quick and accurate tests.

Translational research

Emodepside

New effective, field-adapted drug. Together with Bayer Pharma, we are working to develop emodepside as a new treatment for river blindness with the potential to kill both adult filarial worms and their embryonic larvae, which can cause debilitating and disfiguring clinical symptoms.

Translational research

Dengue pre-clinical profiling

DNDi and our partners are prioritizing drug development for dengue with a focus on pregnant women, young children, and people with comorbidities. In the short term, we are working to repurpose existing direct-acting antivirals and host-directed therapies. Our aim over the medium term is to develop all-new antivirals.

Translational research

LXE408 Novartis for visceral leishmaniasis

A potential new oral treatment for visceral leishmaniasis. DNDi and Novartis initiated a collaboration and licence agreement to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome.

Translational research

DNDI-6899

DNDI-6899 was nominated as a clinical candidate for leishmaniasis following successful pre-clinical development in collaboration with GSK Global Health Unit and the University of Dundee. The promising compound is now among the front-running candidates in our leishmaniasis portfolio.

Translational research

DNDI-6174

DNDi is developing DNDI-6174 as a new chemical entity for the treatment of visceral leishmaniasis with the aim of bringing an additional entity with a novel mechanism of action to the visceral leishmaniasis portfolio, and potentially for the treatment of cutaneous leishmaniasis.

see all projects

Read, watch, share

Loading…
filter by
ALL
News
Press releases
Publications
Scientific articles
see ALL

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

Get in touch

Support us

Work with us